Sorry, took the weekend off accidentally on my daily mission. So here is a little something from a recent email from the Exec Director of LLS, Midwest region.
“In 2015, 6 new agents received FDA approval and 8 potential new agents were given breakthrough status to treat blood cancers. While these new treatment options serve many different blood cancer subtypes, the standard of care for AML has not changed in 40 years. LLS has brought together an unprecedented collaboration of renowned academic researchers and pharmaceutical companies to develop more individualized, effective treatment approaches to BEAT AML.”
This hits very close to home as Cutler’s battle was against AML. While we tout the improvements in the battle against different types of leukemias, it is shocking to see that AML is so far behind. However, it is great to see the resources being put forth to address this and push on in the fight thanks in large part to the efforts of the Leukemia and Lymphoma Society.
No donation is too small!